Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseMyelofibrosis, PrimaryMyelofibrosis, SecondarySubgroupICD10D47.4MeSHPrimary MyelofibrosisSequenceChemotherapyChemo-substanceFedratinibMomelotinibRuxolitinibChemo-substanceFedratinibMomelotinibRuxolitinibChemo-substanceFedratinibMomelotinibRuxolitinibChemo-substanceFedratinibMomelotinibRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlAstheniaBleedingConstipationDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HeadacheHepatotoxicityInfectionsNeuropathyNeutropeniaPainPneumoniaPruritusPyrexiaThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorHarrison CTalpaz MVerstovsek SDiseasehigh-risk primäre Myelofibrose, Post-Polycythaemia Vera-Myelofibrose oder Post-Essentielle Thrombozythämie-MyelofibrosePrimäre Myelofibrose, post-PV oder Post-Essentielle-Thrombozythämie-Myelofibrose, intermediäres oder hohes Risiko, ECOG 0-3OriginGuy's and St. Thomas' National Health Service Foundation Trust, Guy's Hospital, London, COMFORT IIThe University of Texas MD Anderson Cancer Center, Houston, TXUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, USAProtocols in Revision 3 protocols foundProtocols under revision.Fedratinib 400, Primary Myelofibrosis (PID1740 V1.1)Momelotinib 200, Primary Myelofibrosis (PID2573 V1.0)Ruxolitinib 15, Primary Myelofibrosis (PID898 V1.1)
